Patents Assigned to AFFIRIS AG
-
Patent number: 9220762Abstract: A vaccine or immunogenic composition comprising at least two fragments of proprotein convertase subtilisin/kexin type 9 (PCSK9) where one fragment contains at least 9 consecutive residues of residues 153 to 165 of PCSK9 and the other fragment contains at least 9 consecutive residues 209 to 222 of the PCSK9 (SEQ ID NO:9). Methods of treatment for hyperlipidemia, hypercholesterolemia, and atherosclerosis involving administering this vaccine.Type: GrantFiled: September 13, 2012Date of Patent: December 29, 2015Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Bettina Wanko, Markus Windwarder, Gabriele Winsauer, Guenther Staffler, Claudia Juno
-
Publication number: 20150306194Abstract: A method for preventing and/or treating a synucleinopathy, comprising administering a composition containing at least one mimotope of an epitope of alpha-synuclein, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).Type: ApplicationFiled: July 13, 2015Publication date: October 29, 2015Applicant: AFFIRIS AGInventors: Markus MANDLER, Petra Gruber, Frank Mattner, Walter Schmidt
-
Publication number: 20150306191Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: August 28, 2013Publication date: October 29, 2015Applicant: AFFIRIS AGInventors: Sylvia BRUNNER, Gergana GALABOVA, Gabriele WINSAUER, Erika BILCIKOVA, Claudia JUNO, Pola LINZMAYER-HIRT, Birgit SCHUH, Guenther STAFFLER
-
Patent number: 9085636Abstract: The present invention relates to a peptide consisting of 6 to 20 amino acid residues and being derived from amino acid sequence VFKGTLKYGYTTAWWLGIDQSIDFEIDSAI (SEQ ID No. 23), wherein said peptide comprises amino acid sequence WWLGID (SEQ ID No. 24) and antibodies binding to these peptides.Type: GrantFiled: June 11, 2012Date of Patent: July 21, 2015Assignee: AFFIRIS AGInventors: Sylvia Brunner, Mathias Gebhart, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh
-
Publication number: 20150166620Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X3)mKDX2QLGX1 (SEQ ID No. 99), wherein X1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, X2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. X3 is (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, X4 is VVASQLR (SEQ ID No.Type: ApplicationFiled: May 23, 2013Publication date: June 18, 2015Applicant: AFFIRIS AGInventors: Guenther Staffler, Christine Landlinger, Frank Mattner
-
Patent number: 9029327Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: GrantFiled: July 23, 2010Date of Patent: May 12, 2015Assignee: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Publication number: 20150093431Abstract: The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating synucleinopathies, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).Type: ApplicationFiled: April 30, 2013Publication date: April 2, 2015Applicant: AFFIRIS AGInventors: Markus Mandler, Petra Gruber, Frank Mattner, Walter Schmidt
-
Publication number: 20150093432Abstract: The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating ?-amyloidoses including Alzheimer's disease, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).Type: ApplicationFiled: April 30, 2013Publication date: April 2, 2015Applicant: AFFIRIS AGInventors: Markus Mandler, Wolfgang Zauner, Frank Mattner, Walter Schmidt
-
Publication number: 20150071951Abstract: The present invention relates to a vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein said at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9).Type: ApplicationFiled: September 13, 2012Publication date: March 12, 2015Applicant: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Bettina Wanko, Markus Windwarder, Gabriele Winsauer, Guenther Staffler, Claudia Juno
-
Publication number: 20140255435Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (SEQ?ID?NO:?1) (X1)m?(X2)n?(X3)o?X4?X5?H?P?X6 (Formula?I), for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: ApplicationFiled: March 4, 2014Publication date: September 11, 2014Applicant: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Patent number: 8828942Abstract: The present invention relates to peptides or polypeptides for producing medicaments for preventing and/or treating synucleinopathies.Type: GrantFiled: August 20, 2010Date of Patent: September 9, 2014Assignee: Affiris AGInventors: Markus Mandler, Harald Weninger, Radmila Santic, Christian Lahsnig
-
Publication number: 20140242727Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.Type: ApplicationFiled: September 20, 2012Publication date: August 28, 2014Applicant: AFFIRIS AGInventors: Guenther Staffler, Andreas Mairhofer, Achim Schneeberger, Martina Lutterova, Walter Schmidt, Frank Mattner
-
Publication number: 20140234877Abstract: Disclosed is a method for detecting A?-specific antibodies in a biological sample comprising the following steps:—contacting the sample with A?-aggregates or with particles comprising A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and -detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting FACS.Type: ApplicationFiled: September 20, 2012Publication date: August 21, 2014Applicant: AFFIRIS AGInventors: Guenther Staffler, Andreas Mairhofer, Achim Schneeberger, Martina Lutterova, Walter Schmidt, Frank Mattner
-
Publication number: 20140179900Abstract: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.Type: ApplicationFiled: November 21, 2013Publication date: June 26, 2014Applicant: AFFIRIS AGInventors: Sylvia BRUNNER, Petra Luehrs, Frank Mattner, Walter Schmidt, Barbara Wittmann
-
Publication number: 20140147456Abstract: The present invention relates to a peptide consisting of 6 to 20 amino acid residues and being derived from amino acid sequence VFKGTLKYGYTTAWWLGIDQSIDFEIDSAI (SEQ ID No. 23), wherein said peptide comprises amino acid sequence WWLGID (SEQ ID No. 24) and antibodies binding to these peptides.Type: ApplicationFiled: June 11, 2012Publication date: May 29, 2014Applicant: AFFIRIS AGInventors: Sylvia Brunner, Mathias Gebhart, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh
-
Patent number: 8618046Abstract: The present invention relates to a method for treating atherosclerosis and/or atherosclerosis sequelae with a compound that includes FX8(F)oPX9HX10X11X12DX2X3X4X5X6X7 where X8 is G, A, F, Y or K, X9 is E, Y, A, Q, K or S, X10 is H, V, L, F or I, X11 is L, W, S, I, F or Y, X12 is V, T, F or I, X5 is S or Y, X6 is L, A or I, X7 is S, N or T, and o is 0 or 1.Type: GrantFiled: August 8, 2008Date of Patent: December 31, 2013Assignee: Affiris AGInventors: Sylvia Brunner, Petra Luehrs, Frank Mattner, Walter Schmidt, Barbara Wittmann
-
Patent number: 8613931Abstract: The present invention relates to the use of mimotopes in the treatment of diseases associated with ?-amyloid formation and/or aggregation (?-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to A?1-40/42, A?pE3-40/42, A?3-40/42 and A?11-40/42.Type: GrantFiled: June 12, 2009Date of Patent: December 24, 2013Assignee: Affiris AGInventors: Markus Mandler, Christian Gieffers, Frank Mattner, Andrea Dolischka, Oleksandr Otava
-
Publication number: 20130216565Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRAN-ISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).Type: ApplicationFiled: December 21, 2011Publication date: August 22, 2013Applicant: Affiris AGInventors: Guenther Staffler, Christine Landlinger, Frank Mattner
-
Patent number: 8409581Abstract: The present invention relates to the use of mimotopes in the treatment of ?-Amyloidoses including but not limited to Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to non truncated A?1-40/42, and N-terminally truncated forms A?pE3-40/42, A?3-40/42, A?11-40/42, A?pE11-40/42 and A?14-40/42 without interfering with physiological functions of APP signalling.Type: GrantFiled: June 12, 2009Date of Patent: April 2, 2013Assignee: Affiris AGInventors: Markus Mandler, Radmila Santic, Harald Weninger, Edith Kopinits
-
Publication number: 20120269836Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: ApplicationFiled: July 23, 2010Publication date: October 25, 2012Applicant: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka